Stock Ratings / Health Care / RGNX / financials

SRZN (27) EDIT (37) PROK (44) VALN (58) ⌘ Pro Terminal →

REGENXBIO Inc. (RGNX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$7.41 +2.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

REGENXBIO Inc. (RGNX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $489.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNX)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How RGNX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $90.2M

FY24

Rev $83.3M

FY25

Rev $170.4M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$170.4M	52%	-80%	-$193.9M	-$126.4M	-45%
FY 2024	$83.3M	59.7%	-80%	-$227.1M	-$175.6M	-45%
FY 2023	$90.2M	52%	-80%	-$263.5M	-$218.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNX)

✓Walkthrough of RGNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RGNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.39%▲ RESISTANCE BREAKOUT

2026-10-30O $7.38H $7.53L $7.00C $7.41VOL 1.06M

RES: $7.15SUP: $6.37SMA50: $7.98SMA200: $9.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGNX Butterfly Map → + Track RGNX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +104.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RGNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RGNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNX)

Health Care Rank #669 of 1016 ⚔️ SRZN vs RGNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGNX vs. SRZN, EDIT, PROK, VALN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, REGENXBIO Inc. (RGNX) ranks #669 by composite RQD confidence (39/100, grade D-) and #457 by equity capitalization ($489.2M). Within this direct 5-issuer industry benchmark cohort, RGNX leads on earnings valuation at N/A trailing P/E, while RGNX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with RGNX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RGNX ACTIVE REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	Benchmark Subject
SRZN Surrozen Inc.	E	27/100	—	—	-35.0%	-2.93%	$524.4M	/srzn-vs-rgnx →
EDIT Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	/edit-vs-rgnx →
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-rgnx →
VALN Valneva SE	D+	58/100	—	—	—	-0.52%	$541.8M	/valn-vs-rgnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590877

In its most recent audited fiscal period (FY2025, filed 2025-12-31), REGENXBIO Inc. (RGNX) reported GAAP revenue of $170.4M (+104.5% vs. FY2024 revenue of $83.3M , and +88.9% cumulative change since FY2023) , GAAP net income of -$193.9M, operating cash flow of -$124.0M, and free cash flow of -$126.4M (+28.0% YoY). On the balance sheet, RGNX closed FY2025 with $453.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$170.4M	-$193.9M	-$124.0M	-$126.4M	$453.0M	—
FY2024 (FY)	2024-12-31	$83.3M	-$227.1M	-$173.1M	-$175.6M	$466.0M	—
FY2023 (FY)	2023-12-31	$90.2M	-$263.5M	-$218.4M	-$218.4M	—	—

3. RGNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, REGENXBIO Inc. (NASDAQ: RGNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $7.41 (+2.35% 1D, market cap $489.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGNX ranks #669 in composite RQD confidence.

How does RGNX compare to SRZN and EDIT in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RGNX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SRZN (Surrozen Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $524.4M) and EDIT (Editas Medicine Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M). Among the 5-stock peer group, RGNX leads on earnings multiple (N/A) while RGNX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RGNX?

Per RGNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590877), REGENXBIO Inc. generated $170.4M in revenue (+104.5% YoY), -$193.9M in net income, and -$126.4M in free cash flow against $453.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RGNX trading relative to its 50-day, 200-day, and 52-week technical levels?

RGNX last traded at $7.41 (+2.35% on volume of 1,035,633 shares), positioning the stock -7.14% below its 50-day simple moving average ($7.98) and -19.19% below its 200-day simple moving average ($9.17). Across its 52-week range of $5.46 to $16.19, RGNX sits at the 18.2% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.48 to $8.34).

RGNX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is REGENXBIO Inc. (RGNX)?

In FY 2025 (10-K), RGNX converted $170.4M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: RGNX RQD Cockpit RGNX 12M Forecast RGNX Earnings & Move RGNX Dividends & DRIP RGNX Insiders & 13F RGNX Whale Options RGNX Profit Sankey RGNX News & Why